Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
5.12
+0.10 (1.99%)
At close: Mar 23, 2026, 4:00 PM EDT
5.09
-0.03 (-0.59%)
Pre-market: Mar 24, 2026, 8:48 AM EDT
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
53
Market Cap
331.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 316.95K | -1.76M | -84.76% |
| Dec 31, 2021 | 2.08M | -231.57K | -10.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 228.37M |
| XOMA Royalty | 52.15M |
| LENZ Therapeutics | 17.50M |
| Opus Genetics | 14.20M |
| Ovid Therapeutics | 6.61M |
| Armata Pharmaceuticals | 5.05M |
IMRX News
- 6 days ago - Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival - GlobeNewsWire
- 18 days ago - Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 21 days ago - Immuneering to Present at the Leerink Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data - Seeking Alpha
- 2 months ago - Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower - Benzinga
- 2 months ago - Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript - Seeking Alpha
- 2 months ago - Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - GlobeNewsWire